How to buy Vallon Pharmaceuticals stock (Vallon Pharmaceuticals)

Vallon Pharmaceuticals completed its $18 million IPO, selling 2.25 million shares at $8 each. Shares of VLON are available for limit orders on Robinhood.

Our top picks for where to buy Vallon Pharmaceuticals stock

Buy Vallon Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Vallon Pharmaceuticals stock price (NASDAQ: VLON)

Use our graph to track the performance of VLON stocks over time.

Vallon Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-01-24.

52-week range	$0.00 - $0.00
50-day moving average more info button	$2.23
200-day moving average more info button	$0.80
Wall St. target price	$12.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-15.36

Is it a good time to buy Vallon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vallon Pharmaceuticals financials

Gross profit TTM	$100,000
Return on assets TTM	-69.35%
Return on equity TTM	-172.16%
Profit margin	0%
Book value	$0.17
Market Capitalization more info button	$5.4 million

TTM: trailing 12 months

Vallon Pharmaceuticals share dividends

We're not expecting Vallon Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• GlaxoSmithKline PLC ADR (GSK.US) (4.64% forward annual dividend yield)

Have Vallon Pharmaceuticals's shares ever split?

Vallon Pharmaceuticals's shares were split on a 1:30 basis on 23 April 2023 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vallon Pharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Vallon Pharmaceuticals shares which in turn could have impacted Vallon Pharmaceuticals's share price.

Vallon Pharmaceuticals share price volatility

Over the last 12 months, Vallon Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vallon Pharmaceuticals's is -1.1486. This would suggest that Vallon Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vallon Pharmaceuticals has bucked the trend.

To put Vallon Pharmaceuticals's beta into context you can compare it against those of similar companies.

• GlaxoSmithKline PLC ADR (GSK.US): 0.33
• Teva Pharma Industries Ltd ADR (TEVA.US): 0.868

Vallon Pharmaceuticals overview

As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc. , in a reverse merger transaction. Vallon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD.

Frequently asked questions

What percentage of Vallon Pharmaceuticals is owned by insiders or institutions?
Currently 23.417% of Vallon Pharmaceuticals shares are held by insiders and 13.283% by institutions. How many people work for Vallon Pharmaceuticals?
Latest data suggests 2 work at Vallon Pharmaceuticals. When does the fiscal year end for Vallon Pharmaceuticals?
Vallon Pharmaceuticals's fiscal year ends in December. Where is Vallon Pharmaceuticals based?
Vallon Pharmaceuticals's address is: Two Logan Square, Philadelphia, PA, United States, 19103 What is Vallon Pharmaceuticals's ISIN number?
Vallon Pharmaceuticals's international securities identification number is: US92023M1018